Takeda Pharmaceutical Company Limited 보도자료

12월 4일 10:45

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

Takeda (TSE:4502/NYSE:TAK ) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, H...

11월 3일 10:30

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Takeda (TOKYO:4502/NYSE:TAK ) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. The company has upgraded its full ...

11월 3일 10:30

다케다, FY2024 상반기 실적 호조 발표 및 연간 전망 상향 조정

다케다(도쿄증권거래소: 4502/뉴욕증권거래소: TAK )가 FY2024 상반기(2024년 9월 30일 마감 6개월) 실적을 발표하고 성장 및 제품 출시 분야의 지속적인 모멘텀이 성장을 주도하고 있다고 오늘 밝혔다. 회사는 연간 전망 및 경영 지침을 상향 조정하여 예상보다 강...

9월 25일 09:03

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

Takeda (TSE:4502/NYSE:TAK ) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: fruquintinib), a selective oral inhibitor of vasc...

9월 20일 09:49

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Takeda (TSE:4502/NYSE:TAK ) will present additional data from the Phase 2b trials (TAK-861-2001,TAK-861-2002) and long-term extension (LTE) study (TAK-861-2003) of TAK-861 in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) at Sleep Europe 2024...

9월 20일 09:45

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to improving health systems resiliency in low and m...

9월 20일 09:45

다케다, 5개의 신규 글로벌 기업 사회적 책임 파트너십에 3200만달러 이상을 제공해 93개국에서 보건 영향력 확대

다케다(Takeda)(도쿄증권거래소: 4502/뉴욕증권거래소: TAK)가 오늘 5개 신규 글로벌 기업 사회적 책임(Corporate Social Responsibility, CSR) 파트너에게 46억엔(약 3200만달러)을 투입했다. 이는 전 세계 저소득 및 중소득 국가(low and middle-income countries)...

8월 8일 15:25

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda (TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADZYNMA®▼ (recombinant ADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cT...

8월 1일 14:00

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

Takeda (TOKYO:4502/NYSE:TAK ) today announced earnings results for the first quarter of fiscal year 2024 (period ended June 30, 2024), with continued momentum in its Growth & Launch Products driving Core growth at CER and more than offsetting reve...

8월 1일 14:00

다케다, 2024 회계연도 1분기 실적 발표… 성장 및 출시 제품에 의한 강력한 실적, 유망한 후기 단계 파이프라인의 발전

다케다(Takeda)(TOKYO:4502/NYSE:TAK )가 7월 31일(현지 시간) 성장 및 출시 제품의 지속적인 모멘텀이 일정환율(Constant Exchange Rate, CER) 기준으로 핵심 성장을 주도하고 이전 회계연도에 발생한 상당한 독점권 손실로 인한 매출 영향을 상쇄하고도 남는 2024 ...

6월 27일 14:20

Takeda Announces New Assignments of Directors

Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Ta...

6월 27일 14:20

다케다, 새로운 이사 임명 발표

다케다(Takeda)(TOKYO:4502/NYSE:TAK)가 오사카에서 개최된 제148차 정기 주주총회에 이어 이사회 회의와 감사 및 감독 위원회 회의에서 결정된 새로운 이사 선임을 발표했다. 다케다 이사회는 총 14명 중 11명이 사외이사로 재직하고 있어 투명성과 객관성을 확보하...

6월 25일 09:26

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

Takeda (TSE:4502/NYSE:TAK ) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing ant...

6월 23일 13:54

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

Takeda (TSE:4502/NYSE:TAK ) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic pri...

6월 23일 12:47

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

Takeda (TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated...

6월 20일 14:15

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

Takeda (TSE:4502/NYSE:TAK ) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and efficacy of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] ...

6월 20일 14:15

다케다, PNS 연례회의서 만성 염증성 탈수초성 다발성 신경병증 환자 대상 ‘하이큐비아®’의 제3상 ADVANCE-CIDP 3 임상시험 장기 데이터 발표

다케다(Takeda)(TSE:4502/NYSE:TAK) 가 만성 염증성 탈수초성 다발성 신경병증(Chronic Inflammatory Demyelinating Polyneuropathy, CIDP) 환자를 대상으로 하이큐비아®(HYQVIA®)(재조합 인간 히알루로니다아제를 사용한 면역 글로불린 주입 10%(인간))의 안전성과 ...

6월 18일 09:05

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda (TSE:4502/NYSE:TAK ) today announced topline data from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase 3 study that evaluated soticlestat (TAK-935) plus standard of care versus placeb...

6월 16일 10:00

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Takeda (TSE:4502/NYSE:TAK ) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhi...

6월 4일 08:57

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo

Takeda (TSE: 4502/NYSE:TAK ) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data presentations at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine and...

6월 2일 14:57

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

Takeda (TSE:4502/NYSE:TAK ) and Pfizer (NYSE: PFE ) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as...

6월 2일 13:33

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda (TSE:4502/NYSE:TAK ) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 (rADAMTS13) for the...

5월 15일 10:30

Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting

Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill. ...

5월 14일 09:55

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

Takeda (TSE:4502/NYSE:TAK ) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the tre...

5월 13일 10:20

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performa...

Takeda Pharmaceutical Company Limited